Is Mobotinib (Mobosetinib) available in China?

Mobotinib has been launched in China, bringing hope to many patients, but unfortunately, it has not yet been included in medical insurance coverage. Mobocertinib (Mobocertinib), as an oral tyrosine kinase inhibitor developed by Takeda Pharmaceuticals, has been successfully launched in China. The emergence of this drug provides a new treatment option for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. According to official information from the National Medical Products Administration (NMPA), mobotinib has passed priority review and received conditional approval for marketing.

Although Mobotinib has been launched in China and has brought new hope for treatment to specific patient groups, it has not yet been included in the domestic medical insurance system. This means that patients need to pay the full cost of Mobotinib when purchasing it and cannot enjoy the reimbursement policy of medical insurance. This undoubtedly increases the financial burden on patients, especially for patients who require long-term treatment. Drug expenses may become a heavy financial pressure.

Since Mobotinib is an imported innovative drug, its price is relatively high. According to the current market conditions, the price of mobotinib is a considerable burden for many patients. Taking the current market price as an example, a course of Mobotinib treatment may cost tens of thousands of yuan, which is undoubtedly a huge sum of money for ordinary families.

Although Mobotinib is not currently included in the medical insurance, as the country continues to improve the medical security system and attaches great importance to innovative drugs, high-value drugs such as Mobotinib are expected to be gradually included in the scope of medical insurance in the future. This will greatly reduce the financial burden on patients and enable more patients to enjoy the benefits of advanced therapeutic drugs.